



NEWS RELEASE

## Aptinyx to Present at the SVB Securities Global Biopharma Conference

1/31/2023

EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.

A live webcast of the fireside chat will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at <https://ir.aptinyx.com> and will be archived on Aptinyx’s website for 30 days following the event.

### About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including cognitive impairment, post-traumatic stress disorder, and opioid use disorder. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit [www.aptinyx.com](http://www.aptinyx.com).

Source: Aptinyx Inc.

Investor and Media Contact:

Patrick Flavin

Aptinyx Inc.

[ir@aptinyx.com](mailto:ir@aptinyx.com) or [corporate@aptinyx.com](mailto:corporate@aptinyx.com)

847-871-0377

Source: Aptinyx Inc.